Randomized Phase 2 study in front-line setting progressing well, with nine sites actively recruiting and patient treatment ongoing Data update expected in 2027, with trial completion in 2028 Trial-in-progress poster to be presented at ESMO 2026 in October ZURICH-SCHLIEREN, Switzerland and CONCORD,
Developing bispecific Radio-DARPins to engage multiple tumor targets simultaneously, improving precision and therapeutic efficacy Presentation outlines Radio-DARPins’ ability to match target and disease biology for improved outcomes ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., July 15, 2026
Phase 1/2a trial of MP0712, 212 Pb-based DLL3-targeted Radio-DARPin co-developed with Orano Med: Dosing ongoing in first patients; initial data anticipated within the coming months, comprehensive efficacy data expected in 2027 Additional compassionate care work now initiated by the Nuclear
Five sites recruiting in US study of DLL3-targeting 212 Pb-labelled Radio-DARPin MP0712 Dosing ongoing in first patients, consecutively moving to subsequent dosing cycles Initial data anticipated within the coming months, comprehensive efficacy data expected in 2027 ZURICH-SCHLIEREN, Switzerland
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 30, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today
Lead Radio-DARPin MP0712 progressing in Phase 1/2a trial with multiple clinical sites opening and initial clinical data expected in 2026 New data on Radio-DARPins’ amenability to range of therapeutic payloads enable isotope-agnostic strategy for expanding pipeline Strong financial position with
ZURICH-SCHLIEREN, Switzerland and Concord, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics, today announced its attendance and presentations
Positive Phase 1 data confirm MP0317’s tumor-localized CD40 activation with a favorable safety profile in patients with advanced cancer types Pharmacokinetic profile of MP0317 well suited for combination treatment settings, including checkpoint inhibitors Randomized Phase 2 investigator-initiated
MP0632 nominated as first logic-gated Switch-DARPin T cell engager candidate for the treatment of MSLN/EpCAM expressing solid tumors, with preclinical data indicating favorable therapeutic window MP0712, Radio-DARPin candidate in on-going US Phase 1/2a trial, leverages high affinity to DLL3,
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 23, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today
Highly comparable biodistribution profiles of Radio-DARPin candidates labeled with imaging isotopes 177 Lu or 203 Pb allows for rapid expansion of pipeline with multiple therapeutic isotopes ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today
Initiated US Phase 1/2a study of DLL3-targeting 212 Pb-based Radio-DARPin candidate MP0712 for SCLC and other neuroendocrine cancers, co-developed with strategic partner Orano Med; initial data anticipated in 2026 Second Radio-DARPin MP0726 targeting MSLN progressing towards first-in-human imaging;
Partnership with leading nuclear medicine specialist enables advancing pipeline of wholly-owned Radio-DARPin therapeutics for imaging and therapeutic radio-isotopes, including Actinium-225 (225Ac) ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb.
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today
Specific tumor accumulation and attractive biodistribution highly supportive of MP0712 clinical development for treatment of DLL3-expressing cancers Dosimetry data highlight Radio-DARPins as vector for precise delivery of potent alpha-emitting isotopes to tumors MP0712 Phase 1/2a study open in U.S.